Pretomanid Market
The market for Pretomanid was estimated at $459 million in 2024; it is anticipated to increase to $712 million by 2030, with projections indicating growth to around $1.03 billion by 2035.
Report Summary
Market Data
Methodology
Table of Contents
Global Pretomanid Market Outlook
Revenue, 2024
$459M
Forecast, 2034
$955M
CAGR, 2025 - 2034
7.6%
The Pretomanid industry revenue is expected to be around $494.0 million in 2025 and expected to showcase growth with 7.6% CAGR between 2025 and 2034. The emergent and dynamic nature of the Pretomanid market underscores its significance in today's healthcare landscape. Its sustained growth trajectory mirrors the escalating demand for more effective tuberculosis treatments, spurred by an expanding patient pool and the continued prevalence of multi-drug-resistant strains. Increased influx in research and development funding, along with the successful efforts to raise global health awareness, have resulted in a trend of advancing innovations in this field, which further amplifies Pretomanids relevance in modern medicine
As an FDA-approved novel medication, Pretomanid, is part of the bedaquiline, pretomanid and linezolid (BPaL) regimen, a formidable treatment for extensively drug-resistant tuberculosis (XDR-TB) and treatment-intolerant or non-responsive multidrug-resistant tuberculosis (MDR-TB). These cutting-edge applications amplified by evolving trends in healthcare like personalized care, rapid diagnostics, and the thrust on management of drug-resistant infections, have helped catapult Pretomanid into the forefront of tuberculosis treatment.
Market Key Insights
- The Pretomanid market is projected to grow from $459.1 million in 2024 to $955 million in 2034. This represents a CAGR of 7.6%, reflecting rising demand across Tuberculosis Treatment, Antimicrobial Resistance Counteraction and Preclinical Cancer Research.
- Mylan NV, TB Alliance, Sequire Life Sciences are among the leading players in this market, shaping its competitive landscape.
- U.S. and UK are the top markets within the Pretomanid market and are expected to observe the growth CAGR of 4.9% to 7.3% between 2024 and 2030.
- Emerging markets including India, South Africa and Brazil are expected to observe highest growth with CAGR ranging between 8.7% to 10.5%.
- Transition like The Journey Towards Drug Resistance is expected to add $27 million to the Pretomanid market growth by 2030.
- The Pretomanid market is set to add $496 million between 2024 and 2034, with manufacturer targeting Nix-TB Regimen & BPaL Regimen Therapeutic Application projected to gain a larger market share.
- With Rise in multidrug-resistant tuberculosis , and Increased access to tuberculosis diagnostics, Pretomanid market to expand 108% between 2024 and 2034.
Opportunities in the Pretomanid
Forming strategic partnerships with research institutions and other corporations in the pharmaceutical industry could present another avenue for growth. These collaborations can also help in clinical trials, research and development, and in gaining regulatory approvals faster.
Growth Opportunities in North America and Europe
As a crucial pharmaceutical enclave, North America houses numerous pharmaceutical giants invested in the production and distribution of Pretomanid, thereby making it a crucial player in this industry. This regions steady growth can be attributed to its advanced medical infrastructure and the high prevalence of tuberculosis, necessitating the increased use of Pretomanid. The region continues to witness significant investment in research and development activities, fostering innovation, and emphasizing the role of Pretomanid as a vital player in the tuberculosis treatment market. Stiff competition among market players in the region, including pharmacies, hospitals, and research institutions, further escalates the demand for Pretomanid, powering market dynamics.
Europe shows substantial potential for Pretomanid adoption due to its advanced healthcare facilities, research institutions, and an aging population susceptible to tuberculosis. Despite a highly competitive environment characterized by the presence of multiple pharmaceutical companies and a robust regulatory framework, Pretomanid has cemented its position in the European market. The ever-growing need for effective remedies for multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis predicates the regions persistent demand for Pretomanid. Policymakers, industry practitioners, and medical professionals daily interplay and discourse drive the increased availability and prominence of Pretomanid in the European region.
Market Dynamics and Supply Chain
01
Driver: Rise in Multidrug-Resistant Tuberculosis, and Growing Demand in Emerging Economies
The surge in multidrug-resistant tuberculosis cases worldwide presents a significant for the growth of the Pretomanid market. This can also primarily be attributed to Pretomanids effectiveness as the second-line treatment for drug-resistant forms of TB, including multidrug-resistant TB , and extensively drug-resistant TB . Population growth, along with an increase in the incidence of MDR-TB and XDR-TB in low and middle-income countries, has also fueled the demand for Pretomanid. These economies often struggle to provide adequate treatment for TB due to limited resources, enhancing the need for effective solutions like Pretomanid in combating the disease.
also advances in diagnostics and increased accessibility to testing services have also led to more people being diagnosed with TB, including its drug-resistant strains. This surge in diagnoses also drives the demand for Pretomanid, which is also utilized in the treatment of these severe forms of TB.
02
Restraint: Limited Awareness
One key impeding Pretomanid market growth is the limited awareness of this antibiotics benefits in treating specific forms of tuberculosis. Especially in developing countries, there are significant knowledge gaps concerning this medical breakthrough. The lack of understanding and awareness about Pretomanids efficacy often leads to underutilization, thereby affecting market demand negatively and dampening growth potential. Enhanced stakeholder education and public awareness campaigns could play a pivotal role in overcoming this .
03
Opportunity: Expanding into Untapped Markets and Technological Advancements and their Application to Drug Development
Pretomanid, as part of innovative antituberculosis drug regimens, has the potential to tap into new markets globally. Less developed countries with high TB burdens, particularly in Africa and Asia, are in desperate need of effective treatments. Expanding into these markets could have significant implications for the reduction of TB and present an untapped potential for the growth of Pretomanid in terms of both applications and sales.
The fast-paced innovations in drug development technologies could also serve as a significant for Pretomanid. Emerging techniques, such as drug delivery systems and precision medicine, can help improve the drugs efficacy, safety, and patient compliance. This could enable Pretomanid to be used in a broader spectrum of patient populations and therefore expand its current market reach.
04
Challenge: Regulatory barriers
Another major is the stringent regulatory barriers that Pretomanid, like many other pharmaceutical products, faces. Regulatory approvals are essential for the market availability of any drug, including Pretomanid. Unfortunately, these processes can be complex, time-consuming, and differ significantly across geographic regions, hence slowing the drugs commercialization process. These regulatory challenges directly impact market dynamics by restricting the availability of Pretomanid, thus limiting potential market expansion.
Supply Chain Landscape
1
Raw Material Suppliers
Johnson MattheyBASF
2
Intermediate Product Producers
Mylan LaboratoriesLupin Pharmaceuticals
3
API Manufacturers
PfizerSanofi
4
End-Use
Hospital PharmaciesRetail Pharmacies
1
Raw Material Suppliers
Johnson MattheyBASF
2
Intermediate Product Producers
Mylan LaboratoriesLupin Pharmaceuticals
3
API Manufacturers
PfizerSanofi
4
End-Use
Hospital PharmaciesRetail Pharmacies
Use Cases of Pretomanid in Tuberculosis Treatment & Antimicrobial Resistance Counteraction
Tuberculosis Treatment : In the global healthcare industry, the primary use of Pretomanid is found in the innovative regimes designed for combating drug-resistant Tuberculosis. Pretomanid is an integral part of the BPaL regimen , which is extensively employed in treating extensively drug-resistant tuberculosis and multi-drug-resistant tuberculosis . The unique advantage of this regimen is its high cure rate, often exceeding 90% cases, which signals a transformative leap in TB treatment. The most notable global player leveraging this technology is The Global Alliance for TB Drug Development, championing in the development and spread of Pretomanid for TB treatment.
Preclinical Cancer Research : Another application of Pretomanid resides in preclinical investigation aimed at cancer therapeutics. The nitroimidazole class of antibiotics, which includes Pretomanid, showcases potential anti-cancer properties by causing cell death in hypoxic tumour tissues that are typically resistant to conventional treatments. The American biopharmaceutical company Global Cancer Technology is at the forefront of these research applications, demonstrating the potential of Pretomanid in this novel role.
Antimicrobial Resistance Counteraction : Pretomanid also holds great promise in dealing with Antimicrobial Resistance due to its unique mechanism of action. It works by disrupting the bacterial cells energy creation process, leading to cell death.
Recent Developments
Pretomanid, an innovative pharmaceutical product, made significant strides within the healthcare industry. This distinctive medicine, used in treating tuberculosis, has undeniably shaped market trends. In response to an increasing demand for effective tuberculosis treatment, Pretomanids popularity has surged across global markets.
December 2024 : Due to the increasing demand for Pretomanid, leading pharmaceutical company Roche announced a scaling up of their production facilities to improve the global supply chain for the drug.
October 2024 : FDA approves the application of Pretomanid in combination with bedaquiline and linezolid, an advanced regimen for highly drug-resistant forms of tuberculosis, establishing Pretomanid as a major contender in drug-resistant TB treatment.
August 2024 : Johnson & Johnson, in collaboration with Global Alliance for TB Drug Development, initiates an advanced clinical trial for a new drug regimen involving Pretomanid, aiming to enhance TB treatment outcomes and reduce the treatment period.
Impact of Industry Transitions on the Pretomanid Market
As a core segment of the Pharmaceutical industry,
the Pretomanid market develops in line with broader industry shifts.
Over recent years, transitions such as The Journey Towards Drug Resistance and Acceleration of Drug Approvals have redefined priorities
across the Pharmaceutical sector,
influencing how the Pretomanid market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
The Journey Towards Drug Resistance
In recent years, the medical world has observed a significant industry transition towards the fight against drugresistant diseases. Pretomanid, as a novel antituberculosis agent, stands at the forefront of this transition. The staggering growth of drugresistant TB cases worldwide highlights the urgent need for neweffective drugs, and Pretomanid answers this call. The introduction of Pretomanid, especially in combination therapies, has impacted not only the pharmaceutical sphere but also healthcare providers and patients, spurring hope and setting a precedence for future antiTB medication development.
02
Acceleration of Drug Approvals
In tandem with the above, regulatory bodies like the FDA are accelerating the approval of lifesaving drugs like Pretomanid. Traditionally, the process of new drug approval is lengthy, intense and costly. However, recognizing the urgent need for effective medications to control increasing TB cases, faster approval processes are becoming the new norm. This regulatory transition directly impacts drug manufacturers, urging them to expedite their medical innovations.